Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 26 February 2021. Teresa Perry.

Executive Summary

Many elements need to be considered when notified bodies are deciding whether to undertake virtual audits in the context of the new EU medtech regulations. Teresa Perry of BSI Netherlands discussed some of the factors in play.

“We must do everything in our power to get on site and not unnecessarily extend our remote audit practices. This requires a case-by-case risk review, not going further than is necessary to ensure continuous availability of safe and performant devices to patients.” – Teresa Perry, global quality and accreditation manager for BSI Regulatory Services (Medical Devices), BSI Netherlands

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel